Effect of altitude and acetazolamide on sleep and nocturnal breathing in healthy lowlanders 40 y of age or older. Data from a randomized trial.


Journal

Sleep
ISSN: 1550-9109
Titre abrégé: Sleep
Pays: United States
ID NLM: 7809084

Informations de publication

Date de publication:
12 04 2023
Historique:
received: 03 05 2022
revised: 21 08 2022
medline: 13 4 2023
pubmed: 11 11 2022
entrez: 10 11 2022
Statut: ppublish

Résumé

To assess altitude-induced sleep and nocturnal breathing disturbances in healthy lowlanders 40 y of age or older and the effects of preventive acetazolamide treatment. Clinical examinations and polysomnography were performed at 760 m and in the first night after ascent to 3100 m in a subsample of participants of a larger trial evaluating altitude illness. Participants were randomized 1:1 to treatment with acetazolamide (375 mg/day) or placebo, starting 24 h before and while staying at 3100 m. The main outcomes were indices of sleep structure, oxygenation, and apnea/hypopnea index (AHI). Per protocol analysis included 86 participants (mean ± SE 53 ± 7 y old, 66% female). In 43 individuals randomized to placebo, mean nocturnal pulse oximetry (SpO2) was 94.0 ± 0.4% at 760 m and 86.7 ± 0.4% at 3100 m, with mean change (95%CI) -7.3% (-8.0 to -6.5); oxygen desaturation index (ODI) was 5.0 ± 2.3 at 760 m and 29.2 ± 2.3 at 3100 m, change 24.2/h (18.8 to 24.5); AHI was 11.3 ± 2.4/h at 760 m and 23.5 ± 2.4/h at 3100 m, change 12.2/h (7.3 to 17.0). In 43 individuals randomized to acetazolamide, altitude-induced changes were mitigated. Mean differences (Δ, 95%CI) in altitude-induced changes were: ΔSpO2 2.3% (1.3 to 3.4), ΔODI -15.0/h (-22.6 to -7.4), ΔAHI -11.4/h (-18.3 to -4.6). Total sleep time, sleep efficiency, and N3-sleep fraction decreased with an ascent to 3100 m under placebo by 40 min (17 to 60), 5% (2 to 8), and 6% (2 to 11), respectively. Acetazolamide did not significantly change these outcomes. During a night at 3100 m, healthy lowlanders aged 40 y or older revealed hypoxemia, sleep apnea, and disturbed sleep. Preventive acetazolamide treatment improved oxygenation and nocturnal breathing but had no effect on sleep duration and structure. The trial is registered at Clinical Trials, https://clinicaltrials.gov, NCT03561675.

Identifiants

pubmed: 36356042
pii: 6821248
doi: 10.1093/sleep/zsac269
pii:
doi:

Substances chimiques

Acetazolamide O3FX965V0I
AT 760 0

Banques de données

ClinicalTrials.gov
['NCT03561675']

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Sleep Research Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Laura C Graf (LC)

Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Michael Furian (M)

Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Konstantinos Bitos (K)

Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Maamed Mademilov (M)

Department of Respiratory Medicine, National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Ainura Abdraeva (A)

Department of Respiratory Medicine, National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Jana Buenzli (J)

Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Simone Buenzli (S)

Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Shaira Aidaralieva (S)

Department of Respiratory Medicine, National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Ulan Sheraliev (U)

Department of Respiratory Medicine, National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Laura C Mayer (LC)

Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Simon R Schneider (SR)

Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Talant M Sooronbaev (TM)

Department of Respiratory Medicine, National Center for Cardiology and Internal Medicine, Bishkek, Kyrgyzstan.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Silvia Ulrich (S)

Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Konrad E Bloch (KE)

Department of Respiratory Medicine, University Hospital of Zurich, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Zurich, Switzerland.
Swiss-Kyrgyz High Altitude Medicine and Research Initiative, Bishek, Kyrgyz Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH